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Introduction. Neuroblastoma is an embryonal tumor of the sympathetic nervous system and his ﬁrst localization is the adrenal
gland. It is the most common solid tumor in childhood, 90% are diagnosed in the ﬁrst 5 years of life and generally in advanced
stages. Factors of poor prognosis are the abdominal location, the undifferentiated cells, more than one year old and ampliﬁcation
of N-myc gene (shown in 20% of cases). Tumors are sensitive to chemotherapy and radiotherapy. The estimated overall survival is
30-50% CASE: 7 year old girl with a VP shunt valve for hydrocephalus secondary to Chiari malformation type II and she presents
incontinence. At 2 years old is diagnosed with stage IV neuroblastoma, with N-myc ampliﬁed, adrenal primary and metastatic
involvement (lymphnode and bone), achieving complete remission after chemotherapy. Shewas treatedwith adrenalectomy and
autologous hematopoietic stem cell (bone marrow biopsy negative) followed by abdominal radiotherapy given 21Gy. At 5 years
to diagnosed she reports radiographic progression at mediastinal, retroperitoneal and bone. Receive 5 cycles of chemotherapy
with complete response, autologous hematopoietic progenitors and mediastinal radiotherapy given 21Gy by residual lesion. At
present, after 5 years of diagnosis, the disease is stable and without relapse.
Conclusions.We report a casewith poor initial prognosis, diagnosed at 2 years oldwith stage IV, located at abdominal, unresectable
with ampliﬁed N-myc gene, but with a multidisciplinary treatment the patient is asymptomatic and disease-free.
http://dx.doi.org/10.1016/j.rpor.2013.03.168
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Six year old, female patient. Oncological history: Due to a gastrointestinal affectation and a severe general involvement, she visits
the ERwhere she is found to haveGI bleeding and a tumor in hypogastrium. She is urgently surgically intervened onApril 15, 1981,
and a mass 10 cm×8 cm in size is removed from anterior and posterior bladder, which at that moment has tore and is bleeding
profusely and has a cerebroid aspect; the pathological anatomy is consistent with a grade III embryonal rhabdomyosarcoma.
Upon this ﬁnding, chemotherapy is decided upon according to protocol (Vincrisul, actinomycin D and cyclophosphamide during
4 cycles). Later on, she is giving a RTE-2D treatment with Cobalt 60 by means of 4 ﬁelds, two laterals and a anterior and posterior
that encompass the entire volumen of the tumorectomy. Total dosage of 42Gy. Fractionation 5×150 cGy. Renal protección was
given at lateral and posterior ﬁelds, and hepathic protectionwith an anterior ﬁeld. The treatment lasted from10/06/81 to 22/07/81.
She tolerated it well. Evolution: Patient remained in follow ups by pediatrics. Following her diagnosis of primary hypogonadism,
secondary to pelvic radiotherapy, a substitute hormonal therapy with ethinilestradiol is started in 1992 but was suspended due
to lack of growth. She then, received growth hormone but discordant corporal proportions were observed. Reason for which she
was given microgynon, experimenting menarche that same year. At age 17, in 1993 during physical exploration, the patient is
found to have a grade I thelarche, grade II pubarche and grade III axilarche. From there on she has had a normal secondary sexual
development. Current status Toxicity outstanding: sterility. Currently this patient is symptom free (ILE 360 months).
http://dx.doi.org/10.1016/j.rpor.2013.03.169
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Introduction. Patient diagnosed at the age of 5 from a posterior fossa meduloblastoma. At the age of 21, new diagnosis of a PECOMA
uterus tumor. Long survival with low side effects.
General review. Medulloblastoma is the most frequent solid tumor (CNS) in children. Survival rate at ﬁve years is <50%. Common
treatment is based on surgery, radiation and chemotherapy.Wide range of side effects associatedwith treatment. Uterus PECOMA
is an infrequent (<1 case in 100,000) tumor that is related with the Tuberous Sclerosis (TS) spectrum of diseases. It is considered
as an unknown behavior malignant tumor. Recent data show relation between TS tumorigenic pathways and medulloblastoma.
Our case. Our patient suffer from Tuberous Sclerosis. She was diagnosed and treated at the age of 5 with complete surgical
resection followed by chemoradiation (30Gy to craniospinal axis and 50Gy to posterior fossa as a boost with a 2D planning) and
adyuvant chemotherapy. At the age of 21, in March 2012, in a gynecological review due to metrorrhagia, she was diagnosed from
a PECOMA uterus tumor. Simple hysterectomy was done. No adjuvant treatment associated. No evidence of recurrence of both
tumor at the present time. Carrying out a normal life.
